TREATMENT OF PATIENTS WITH SMALL CELL LUNG CANCER

A. 262例小细胞肺癌患者接受了治疗 从1977年到1993年用了5种不同的化疗方案患者 开始治疗时被指定为正常、肥胖或严重肥胖 并在其初始治疗期间评估其毒性。有 未发现增加的身体 质量指数和治疗或存活的毒性。 B。54例局限期小细胞肺癌患者， 依托泊苷顺铂加每日两次胸部放疗治疗。的 中位生存期为21.3个月，1年时实际生存率为83%， 2年时的精算生存率为43%，5年时为19%。 C.足叶乙甙/顺铂联合二次化疗治疗局限期患者 每日胸部放射治疗比101例局限期患者生存时间长 接受两种不同的环磷酰胺化疗 每日一次胸部放疗。无差异 广泛期小细胞肺癌患者的生存率 在过去的20年里接受了5种不同的化疗方案。

A. Two hundred sixty-two patients with small cell lung cancer were treated with 5 different chemotherapy regimens from 1977 through 1993. Patients starting on treatment were designated as normal, obese or severely obese and their toxicity was assessed during their initial treatment. There were no consistent associations of significance found between increasing body mass index and toxicity from therapy or survival. B. Fifty-four patients with limited stage small cell lung cancer were treated with etoposide cisplatin plus twice daily chest radiotherapy. The median survival is 21.3 months with actual survival of 83% at l year, actuarial survival of 43% at 2 years, and 19% at 5 years. C. The limited-stage patients treated with etoposide/cisplatin plus twice daily chest radiation therapy lived longer than 101 limited stage patients treated with two different cyclophosphamide-based chemotherapy combinations and once daily chest radiation. There was no difference in the survival of patients with extensive stage small cell lung cancer treated with 5 different chemotherapy regimens over the past 20 years.